Research programme: anti epithelial cell adhesion molecule antibodies - Affitech A/SAlternative Names: AT 003; EpCAM Antibodies
Latest Information Update: 16 Jul 2016
At a glance
- Originator Affitech A/S
- Class Antibodies
- Mechanism of Action Epithelial cell adhesion molecule inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Norway
- 03 Aug 2009 Preclinical trials in Cancer in Norway (unspecified route)